Key result
Alirocumab improves intracranial stenosis regression by ~9 percentage points vs. statin alone at 6 months.
Why the study?
Does adjunctive alirocumab added to high-intensity statin therapy reduce intracranial artery stenosis on vessel-wall MRI compared to high-intensity statin alone in patients with acute ischemic stroke or TIA due to symptomatic intracranial atherosclerotic stenosis?
RCT (n=62)
Open-label, blinded-endpoint
1:2 ratio
No
Does adjunctive alirocumab added to high-intensity statin therapy reduce intracranial artery stenosis on vessel-wall MRI compared to high-intensity statin alone in patients with acute ischemic stroke or TIA due to symptomatic intracranial atherosclerotic stenosis?
Answers are grounded in this paper and cite their sources.
Adding alirocumab to high-intensity statin therapy for 6 months significantly promotes intracranial atherosclerotic plaque regression and achieves superior LDL-C lowering (<55 mg/dL in 85% vs 13%) in patients with acute symptomatic intracranial stenosis.
Background Intracranial atherosclerotic stenosis is a major cause of ischemic stroke with high recurrence rates despite intensive therapy. The efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) as adjunctive treatment in intracranial atherosclerotic stenosis remains unclear. Methods We conducted a prospective, randomized, open‐label, blinded‐end point trial involving 62 patients with symptomatic intracranial atherosclerotic stenosis. Participants were randomized 1:2 to receive either a PCSK9i (alirocumab 75 mg every 2 weeks) plus high‐intensity statin or high‐intensity statin alone for 6 months. The primary outcome was the change in intracranial artery stenosis measured by high‐resolution vessel‐wall magnetic resonance imaging. Secondary outcomes included plaque enhancement volume, low‐density lipoprotein cholesterol target achievement (<55 mg/dL), recurrent stroke events, modified Rankin Scale, and safety assessments. Results Among 62 participants (median age, 66 years; 77% men), 60 completed the study per protocol. At 6 months, median stenosis reduction was greater in the PCSK9i group (7.1%; interquartile range, 3.6–12.8%) than in controls (−1.2%; interquartile range, −4.9–4.5%) ( P <0.001). The baseline‐adjusted mean difference estimated using a generalized linear model was 8.9 percentage points (95% CI, 5.1–12.6). Both groups showed significant reduction in plaque enhancement volume, but between‐group difference was not significant (4.3 versus 4.0 mm 3 ; P =0.79). Low‐density lipoprotein cholesterol <55 mg/dL was achieved in 85% of the PCSK9i group versus 13% of controls ( P <0.01). Recurrent stroke occurred in 5% versus 13% of patients ( P =0.34). No serious adverse events were reported in either group. Conclusions In patients with symptomatic intracranial atherosclerotic stenosis, adjunctive PCSK9i therapy significantly reduced intracranial stenosis and improved low‐density lipoprotein cholesterol control over 6 months. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05001984.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) conducted an RCT in Symptomatic intracranial atherosclerotic stenosis (ICAS) (n=62). Alirocumab plus high-intensity statin vs. High-intensity statin alone (rosuvastatin 20 mg or atorvastatin 40-80 mg daily) was evaluated on Change in intracranial artery stenosis (%) at 6 months on high-resolution vessel-wall MRI (MD 8.9 percentage points, 95% CI 5.1-12.6, p=<0.001). Adjunctive alirocumab increased intracranial stenosis reduction at 6 months compared to statin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: